Granisetron Hydrochloride NDC 51991-735

NDC codes

FDA NDC Directory

Product NDC (as listed)51991-735Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51991-0735Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51991-735-20	51991073520	2 BLISTER PACK in 1 CARTON (51991-735-20) / 10 TABLET in 1 BLISTER PACKMarketed from Jun 22, 2009
51991-735-32	51991073532	1 BLISTER PACK in 1 CARTON (51991-735-32) / 2 TABLET in 1 BLISTER PACKMarketed from Jun 22, 2009

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Granisetron Hydrochloride
Generic name (nonproprietary): granisetron hydrochloride
Active ingredients: Granisetron hydrochloride — 1 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Breckenridge Pharmaceutical, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078969
Marketing start: Jun 22, 2009
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin 3 Receptor Antagonists (Mechanism)
Identifiers: Product ID 51991-735_1919cca7-47e5-4474-8ad1-a49275d4f85bSPL ID 1919cca7-47e5-4474-8ad1-a49275d4f85bSPL set ID df4b6775-4337-41e0-815a-b064d98c3fe1RxCUI 310599UNII 318F6L70J8UPC 0351991735328
Pharmacologic class: Serotonin-3 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451991073520 followed by a unit qualifier and the quantity

Package 51991-0735-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 29, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Granisetron hydrochloride tablets USP are indicated for the prevention of: Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 078969

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078969
Product	Strength	Form · route	Labeler	Product NDC
Granisetron hydrochloride	Granisetron hydrochloride 1 mg/1	Tablet, Film coatedOral	Natco Pharma Limited	63850-0005